Welcome to our dedicated page for Teva Pharmaceutical Industries SEC filings (Ticker: TEVJF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Teva Pharmaceutical Industries's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Teva Pharmaceutical Industries's regulatory disclosures and financial reporting.
TEVA PHARMACEUTICAL INDUSTRIES LTD executive Richard Daniell, EVP, Europe Commercial, reported exercising restricted share units and related share sales. On March 3, 2026, he converted restricted share units into ordinary shares at a price of $0.0000 per share through multiple derivative exercises.
He then sold a total of 128,985 ordinary shares in open-market transactions at a weighted average price of $32.3599 per share, with actual prices ranging from $31.72 to $32.865. These sales were made under a Rule 10b5-1 trading plan adopted on November 10, 2025 and include shares sold to cover tax withholding obligations tied to RSU vesting and performance-based awards. Following these transactions, he directly held 123,127 ordinary shares, and certain restricted share units continue to vest, including tranches through March 4, 2027.
Teva Pharmaceutical Industries officer Mark Sabag exercised restricted share units on March 3, 2026, converting 24,900 and 141,478 units into the same number of ordinary shares at $0.00 per share. After these settlements, he directly held 219,206 ordinary shares.
TEVA PHARMACEUTICAL INDUSTRIES LTD reported insider equity transactions by Interim Chief Legal Officer Brian Savage. On March 3, 2026, he exercised 3,461 Restricted Share Units, converting them into 3,461 Ordinary Shares at a stated price of $0.0000 per share.
Following this conversion, he held 4,200 Ordinary Shares, then sold 1,274 Ordinary Shares at a weighted average price of $32.3599 per share to cover tax withholding obligations, leaving 2,926 Ordinary Shares held directly.
Teva Pharmaceutical Industries Ltd reported insider transactions by President and CEO Francis Richard on March 3, 2026. He exercised restricted share units into ordinary shares and then sold a portion of the resulting holdings.
The filing shows exercises or conversions of restricted share units into 67,231 and 891,315 ordinary shares at a stated price of $0.0000 per share, and open-market sales totaling 442,935 ordinary shares at a weighted average price of $32.3599 per share, with individual sale prices ranging from $31.72 to $32.865. The transactions were effected under a Rule 10b5-1 trading plan, and some shares were sold to cover tax withholding obligations related to vesting restricted share units.
After these transactions, Richard directly held 1,121,382 ordinary shares. Footnotes explain that restricted share units were originally granted or earned based on performance and time-based vesting criteria and that each unit represents a right to receive one ordinary share or its cash value.
Teva Pharmaceutical Industries Ltd. executive vice president and chief financial officer Eliyahu Sharon Kalif exercised restricted share units into ordinary shares on March 3, 2026.
He converted 49,800 and 141,478 restricted share units, resulting in 248,756 ordinary shares held directly as of that date.
Teva Pharmaceutical Industries Limited reports a Form 144 notice for proposed sale of 20,461 ordinary shares tied to a restricted share unit award vesting on 03/04/2026. The filing lists Citigroup Global Markets Inc. as the broker and classifies the disposition as compensation-related.
Teva Pharmaceutical Industries reported insider sales by Richard Francis. The filing shows sales of 447,678 ordinary shares on 02/17/2026 for $15,324,799.05 and 442,935 ordinary shares on 03/03/2026 for $14,333,332.31. The notice also lists a Restricted Share Unit award vesting of 50,223 ordinary shares with a date labeled 03/04/2024 and an entry dated 03/04/2026 under compensation.
Teva Pharmaceutical Industries Limited Form 144 lists a proposed sale of ordinary shares to be handled through Citigroup Global Markets. The filing also records a prior sale by Eric Hughes of 80,762 shares on 03/03/2026 for $2,613,450.24 and a restricted share unit award of 23,251 scheduled with a 03/04/2026 vesting/compensation reference.
Teva Pharmaceutical Industries Limited reported a proposed sale of 91,345 ordinary shares through Citigroup Global Markets Inc. with an apparent aggregate value of $2,983,515.95, dated 03/04/2026. The filing lists recent dispositions by Daniell Richard of 115,468 shares on 12/09/2025 for $3,311,131.04 and 128,985 shares on 03/03/2026 for $4,173,941.70.
Teva Pharmaceutical Industries reported a Form 144 notice relating to proposed sales of its ordinary shares. The filing lists a restricted share unit award of 3,461 shares vesting on 03/03/2026. The filing also discloses insider sales by Brian Savage: 450 shares sold on 01/30/2026 and 1,000 shares sold on 12/12/2025.